CONCLUSION
Based on the analysis of the collected data, it appears that IL-8 may not be a suitable prognostic marker for the conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS). Conversely, the CXCL13 marker shows greater promise in this regard. We observed an inclination towards higher CXCL13 levels in patients who transitioned from CIS to relapsing-remitting MS (RRMS). These findings are consistent with previously published studies that have highlighted the prognostic significance of CXCL13 in patients with CIS.
Considering the evidence from our results and those of other studies, it is conceivable that CXCL13 holds potential as an indicator of inflammatory activity in individuals with MS, and its inclusion in routine clinical practice should be contemplated. Nonetheless, these findings should be validated through further investigation involving a larger patient cohort.